Science

Rafael Grochot: The safety and activity of FGFR inhibitors in early-phase clinical trials

Rafael Grochot/LinkedIn

Apr 18, 2025, 19:10

Rafael Grochot: The safety and activity of FGFR inhibitors in early-phase clinical trials

Rafael Grochot, Medical Oncologist – Clinical Trial Specialist at Sarah Cannon Research Institute, shared a post on LinkedIn about a paper he co-authored with colleagues published in JCO Precision Oncology:

“Proud of our work on safety and activity of FGFR inhibitors in early phase clinical trials published today on American Society of Clinical Oncology (ASCO) JCO Precision Oncology, JCO Journals.”

“Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials”

Authors: Rafael Grochot, Kroopa Joshi, Antonella Cammarota, Rachel Woodford, Gethini Sathanantham, Anja Williams, Tobias Arkenau, Vivek Subbiah, Charles Swanton, Elisa Fontana.

More posts featuring Rafael Grochot.

American Society of Clinical Oncology Anja Williams Antonella Cammarota ASCO cancer Charles Swanton Elisa Fontana FGFR inhibitors Fibroblast Growth Factor Receptor Inhibitors Gethini Sathanantham JCO Journals JCO Precision Oncology Kroopa Joshi OncoDaily Oncology Rachel Woodford Rafael Grochot Tobias Arkenau Vivek Subbiah

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute